Figure S6 from A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity

作者：Baocun Li, Shiyong Gong, Nianying Zhang, Beilei Shi, Zhou Lv, Yu Zhang, Naren Gaowa, Liqin Dong, Danqing Wu, Jianfu Wu, Fan Liu, Rui Zhang, Ramin Behzadigohar, Vinod Ganju, Chengbin Wu, Xuan Wu · 年份：2026 · DOI：10.1158/1535-7163.32713074 · 研究领域：Monoclonal and Polyclonal Antibodies Research、Immunotherapy and Immune Responses、CAR-T cell therapy research

<p>Supplementary. Fig. 6. In vivo anti-tumor activity of EMB-09 parental mAbs in transgenic C57B/6 mice. a The anti-tumor efficacy of tested antibodies alone or in combination was evaluated in hOX40 transgenic C57B/6 mice. MC38 tumor bearing mice were treated with the indicated antibodies 7 days after tumor implantation. 5 mg/kg of antibodies treated with 3 times at a 3-days’ interval (n = 8 per group, error bar: SEM). b The anti-tumor efficacy of tested antibodies was evaluated in hPD-L1 transgenic C57B/6 mice. Mice were subcutaneously inoculated with MC38-hPD-L1 tumor cells. 7 days after tumor implantation, mice were randomly allocated to different groups and treated with the indicated antibodies (10 mg/kg) for four times at a 3-days’ interval. Tumor volume was assessed. (n = 8 per group, error bar: SEM). 44-16 is the parental anti-OX40 mAb of EMB-09, 86-64 is the parental anti-PD-L1 mAb of EMB-09, Atezolizumab* is the Atezolizumab analogue.</p>